Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...
Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
4d
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders
Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.
Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...
A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...
Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback